Table 1. Characteristics of blood samples and tissue samples.
| Characteristic | Blood samples | Tissue samples |
|---|---|---|
| Number of patients (n) | 496 | 1,504 |
| Age (mean ± SD) | 61.58±12.48 | 57.42±14.67 |
| Sex, n (%) | ||
| Male | 314 (63.31) | 866 (57.58) |
| Female | 182 (36.69) | 638 (42.42) |
| Cancer, n (%) | ||
| AUBT (abdominal tumor) | 1 (0.20) | 7 (0.47) |
| ASC (lung adenosquamous carcinoma) | 1 (0.20) | 1 (0.07) |
| BLCA (bladder cancer) | 3 (0.60) | 23 (1.53) |
| BRCA (breast cancer) | 6 (1.21) | 33 (2.19) |
| CESC (cervical squamous cell carcinoma) | 12 (2.42) | 13 (0.86) |
| CHOL (cholangiocarcinoma) | 9 (1.81) | 46 (3.06) |
| COAD (colon adenocarcinoma) | 11 (2.22) | 152 (10.1) |
| COAD READ (colorectal cancer) | 4 (0.81) | 31 (2.06) |
| DUCA (duodenal cancer) | 1 (0.20) | 5 (0.33) |
| ESCA (esophageal cancer) | 11 (2.22) | 18 (1.2) |
| GACA (gastrointestinal cancer) | 1 (0.20) | 2 (0.13) |
| GBC (gallbladder carcinoma) | 1 (0.20) | 9 (0.6) |
| HCC (hepatocellular carcinoma) | 98 (19.8) | 84 (5.59) |
| HNSC (head and neck squamous cell carcinoma) | 3 (0.60) | 6 (0.4) |
| KICA (kidney cancer) | 5 (1.01) | 33 (2.19) |
| KIPAN (mixed kidney cancer) | 1 (0.20) | 1 (0.07) |
| KIRC (kidney renal clear cell carcinoma) | 3 (0.60) | 2 (0.13) |
| LEIO (leiomyosarcoma) | 1 (0.20) | 3 (0.2) |
| LUAD (lung adenocarcinoma) | 210 (42.30) | 482 (32.04) |
| LUSC (lung squamous cell carcinoma) | 7 (1.41) | 36 (2.39) |
| MEDI (mediastinal tumor) | 1 (0.20) | 0 (0) |
| NACA (nasopharyngeal carcinoma) | 6 (1.21) | 7 (0.47) |
| NECA (neuroendocrine carcinoma) | 1 (0.20) | 2 (0.13) |
| NHL (non-Hodgkin’s lymphoma) | 1 (0.20) | 4 (0.27) |
| NSCLC (non-small cell lung cancer) | 5 (1.01) | 5 (0.33) |
| ORCA (oropharynx carcinoma) | 4 (0.81) | 3 (0.2) |
| Other (other) | 3 (0.6) | 14 (0.93) |
| OVCA (ovarian cancer) | 6 (1.21) | 26 (1.73) |
| PAAD (pancreatic adenocarcinoma) | 25 (5.04) | 42 (2.79) |
| PAGLCA (parotid gland carcinoma) | 1 (0.2) | 3 (0.2) |
| PPC (primary peritoneal carcinoma) | 4 (0.81) | 8 (0.53) |
| PRAD (prostate adenocarcinoma) | 6 (1.21) | 16 (1.06) |
| READ (rectal adenocarcinoma) | 11 (2.22) | 114 (7.58) |
| SARC (sarcoma) | 3 (0.60) | 20 (1.33) |
| SCLC (small cell lung cancer) | 3 (0.60) | 10 (0.66) |
| SEVECA (seminal vesicle carcinoma) | 1 (0.2) | 0 (0) |
| SICA (sinonasal carcinomas) | 2 (0.4) | 6 (0.4) |
| STAD (stomach adenocarcinoma) | 14 (2.82) | 72 (4.79) |
| STES (esophagocardial cancer) | 3 (0.60) | 9 (0.6) |
| THCA (thyroid cancer) | 2 (0.40) | 1 (0.07) |
| TOCA (tongue cancer) | 1 (0.20) | 0 (0) |
| UCEC (uterine corpus endometrial carcinoma) | 2 (0.40) | 13 (0.86) |
| URCA (ureter carcinoma) | 1 (0.20) | 4 (0.27) |
| UVM (uveal melanoma) | 1 (0.20) | 5 (0.33) |
| ACC (adrenocortical carcinoma) | 0 (0) | 3 (0.2) |
| AGCS (archos adenocarcinoma) | 0 (0) | 1 (0.07) |
| AMCA (bowel cancer) | 0 (0) | 5 (0.33) |
| BOCA (cecum cancer) | 0 (0) | 21 (1.4) |
| CECA (cecum cancer) | 0 (0) | 3 (0.2) |
| ESCC (esophageal squamous cell carcinoma) | 0 (0) | 2 (0.13) |
| GBM (glioblastoma) | 0 (0) | 7 (0.47) |
| GCT (germ cell tumor) | 0 (0) | 2 (0.13) |
| GECECA (germ cell carcinoma) | 0 (0) | 1 (0.07) |
| GLIO (gliomas) | 0 (0) | 66 (4.39) |
| MB (medulloblastic carcinoma) | 0 (0) | 3 (0.2) |
| MENI (meningioma) | 0 (0) | 6 (0.4) |
| MESO (mesothelioma pleura) | 0 (0) | 3 (0.2) |
| ONB (olfactory neuroblastoma) | 0 (0) | 1 (0.07) |
| PECA (penis carcinoma) | 0 (0) | 1 (0.07) |
| THYM (thymic carcinoma) | 0 (0) | 4 (0.27) |
| UBC (urothelium carcinoma) | 0 (0) | 4 (0.27) |
SD, standard deviation.